Hyperion Defi (HYPD) Finished Goods (2023 - 2024)
Hyperion Defi (HYPD) posted quarterly Finished Goods of $427217.0 for Q3 2024, up 1643.32% year-over-year from $24506.0 in Q4 2023, and up 49.25% quarter-over-quarter from $286236.0 in Q2 2024.
Hyperion Defi (HYPD) Finished Goods (2023 - 2024) Analysis & Trends
Hyperion Defi (HYPD) has reported Finished Goods for 2 consecutive years, with $427217.0 the latest figure, recorded in Q3 2024.
- In Q3 2024, Finished Goods rose 1643.32% year-over-year to $427217.0; the TTM figure through Sep 2024 stood at $427217.0 (up 1643.32% YoY), while the FY2023 annual figure was $30683.0, changed N/A from the prior year.
- Finished Goods rose to $427217.0 in Q3 2024 per HYPD's latest filing, from $286236.0 in the prior quarter.
- Across five years, Finished Goods topped out at $452218.0 in Q1 2024 and bottomed at $24506.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Hyperion Defi | 44.93 Mn | 35.29 Mn | 357,693.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 427,217.00 |
| Jun 30, 2024 | 286,236.00 |
| Mar 31, 2024 | 452,218.00 |
| Dec 31, 2023 | 30,683.00 |
| Sep 30, 2023 | 24,506.00 |